Merck Completes R&D Leadership Transition To Kim; Spotlight On Genomics
Executive Summary
Merck's effort in genomics will take on a new focus under new R&D head Peter Kim, PhD
You may also be interested in...
Merck Won’t Go Hollywood: In-House R&D Still Focus As Outside Deals Expand
Merck is on a pace to sign 50 outside R&D alliances during 2003
Merck Won’t Go Hollywood: In-House R&D Still Focus As Outside Deals Expand
Merck is on a pace to sign 50 outside R&D alliances during 2003
Singulair Allergy Approval Will Drive Sales Despite OTC Claritin, Merck Says
Merck's Singulair allergic rhinitis indication will help accelerate growth for the asthma drug in 2003, despite the onset of OTC Claritin, Investor Relations Senior Director Mark Stejbach told investors on a Dec. 5 conference call